| Literature DB >> 35345621 |
Liang Zhou1, Xiuwu Hu1, Zhen Yu2, Lihui Yang3, Renhong Wan3, Haolin Liu3, Ying Wang1.
Abstract
Objective: To evaluate the efficacy and safety of acupuncture in the treatment of poststroke insomnia.Entities:
Year: 2022 PMID: 35345621 PMCID: PMC8957466 DOI: 10.1155/2022/5188311
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1The selection process of the literature.
Characteristics of the included literature.
| Study cohort | Country | No. | Age | Interventions | Course (days) | Outcome | |
|---|---|---|---|---|---|---|---|
| (C/T) | (C/T) | C | T | ||||
| Gao et al., 2009 [ | China | 54 (26/28) | 63.40 ± 7.50/64.60 ± 6.20 | Estazolam (1 mg, Qd) | Acupuncture (Shuigou-GV26, Shaoshang-LU11, Yinbai-SP1, Daling-PC7, Shenmai-BL62, Fengfu-GV16, Jiache-ST6, Chengjiang-RN24, Quchi-LI11, etc.), Qd | 30 | ①, ② |
| Hao et al., 2016 [ | China | 54 (27/27) | 58.02 ± 7.96/57.71 ± 8.25 | Estazolam (0.5–1 mg, Qd) | Acupuncture (Zusanli-ST36, Guanyuan-RN4, Hegu-LI4, Baihui-GV20, Quchi-LI11, etc.) | 28 | ①, ② |
| Hou et al., 2018 [ | China | 60 (30/30) | 62.00 ± 5.00/61.00 ± 5.00 | Diazepam (2.5 mg, Qn) | Acupuncture (Baihui-GV20, Ningshen, Neiguan-PC6, Taiyang-EX-HN5, Sanyinjiao-SP6, Zhaohai-KI6, Zusanli-ST36), 40 min, Qd | 30 | ① |
| Huang et al., 2019 [ | China | 60 (30/30) | 59.47 ± 8.34/60.17 ± 10.12 | Estazolam (1-2 mg, Qd) | Acupuncture and moxibustion of invigorating spleen and regulating spirit (Zhongwan-RN12, Tianshu-ST25, Zusanli-ST36, etc.) + Yintan-GV29 + Zusanli-ST36 moxibustion, 30 min, 5 times/week, 4 weeks | 28 | ①, ② |
| Jia, 2010 [ | China | 60 (30/30) | 63.10 ± 7.00/62.50 ± 6.40 | Estazolam (2 mg, Qd) | Acupuncture (Shenmen-HT7, Sanyinjiao-SP6, Shenting-GV24, Sishencong-EX-HN1, Neiguan-PC6, Taichong-LR3, Taixi-KI3), 20–30 min, 5 times/week | 28 | ①, ②, ③ |
| Ji, 2016 [ | China | 60 (30/30) | 65/63 | Estazolam (2 mg, Qd) | Acupuncture (Sanyinjiao-SP6, Baihui-GV20, Anmian, Neiting-ST44, Fenglong-ST40, Shenting-GV24, Shenmen-HT7, etc.), 30 min, Qd | 28 | ①, ③ |
| Li, 2007 [ | China | 64 (32/32) | 67.30 ± 8.30/69.80 ± 7.10 | Diazepam 2.5 mg or estazolam 1 mg, Qd | Acupuncture (Shenmen-HT7, Sanyinjiao-SP6, Shenting-GV24, Sishencong- EX-HN1, Neiguan-PC6, etc) + auricular point: Shenmen, 20∼30 min, 6 times/week | 28 | ①, ② |
| Li, 2015 [ | China | 80 (40/40) | 50.00 ± 3.00/51.10 ± 2.40 | Estazolam (2 mg, Qd) | Acupuncture (Shenmai-BL62, Zhaohai-KI6, Dazhui-GV14, Guanyuan-RN4, Taichong-LR3, Quchi-LI11, etc.), 20 min, 5 times/week | 28 | ①, ② |
| Liu, 2006 [ | China | 62 (30/32) | 67.50 ± 8.20/69.90 ± 6.90 | Diazepam 2.5 mg or estazolam 1 mg, Qd | Acupuncture (Shenmen-HT7, Sanyinjiao-SP6, Shenting-GV24, Sishencong- EX-HN1, Neiguan-PC6, etc.) + auricular point (Shenmen), 30 min, 5 times/week | 28 | ①, ② |
| Liu et al., 2017 [ | China | 70 (35/35) | 63.02 ± 7.79/62.08 ± 7.82 | Estazolam (1 mg∼2 mg, Qd) | Acupuncture (Baihui-GV20, Shenting-GV24, Guanyuan-RN4, Qihai-RN6, Shenmen-HT7, Sanyinjiao-SP6, etc.), 30 min, 5 times/week | 28 | ①, ②, ③ |
| Liu and Zhang, 2017 [ | China | 72 (36/36) | 52.08 ± 6.19/52.31 ± 8.26 | Estazolam (1 mg, Qd) | Auricular acupuncture (Xin, Shenmen, Neifenmi, Jiaogan, etc.), every 3 days, 2 times/week | 28 | ①, ② |
| Lu et al., 2008 [ | China | 50 (25/25) | 62.40 ± 4.88/61.48 ± 3.72 | Diazepam (5 mg, Qd) | Acupuncture (Shenting-GV24, Baihui-GV20, Fengfu-GV16, Shendao-GV11, Shenshu-BL23, Taixi-KI3, Shenmen-HT7, Neiguan-PC6), 30 min, 6 times/week | 28 | ①, ② |
| Ma et al., 2016 [ | China | 80 (40/40) | 63.70 ± 4.94/61.88 ± 5.16 | Estazolam (1 mg, Qd) | Acupuncture (Baihui-GV20, Shenting-GV24, Guanyuan-RN4, Qihai-RN6, Shenmen-HT7, Sanyinjiao-SP6, etc.), 30 min, Qd | 28 | ①, ②, ③ |
| Mi et al., 2009 [ | China | 80 (40/40) | 63.11 ± 11.96/65.28 ± 10.55 | Estazolam (1 mg, Qd) | Acupuncture (Shuigou-GV26, Neiguan-PC6, Sanyinjiao-SP6, JIquan-HT1, Chize-LU5, Weizhong-BL40, Zhongwan-RN12, etc.), 30 min, 5 times/week | 28 | ①, ② |
| Qin et al., 2019 [ | China | 70 (35/35) | 51.80 ± 5.10/52.50 ± 5.30 | Estazolam (1 mg, Qd) | Acupuncture (Shendao-GV11, Shuigou-GV26, Shenting-GV24, Shenshu-BL23, Taixi-KI3), 50 min, Qd | 28 | ①, ② |
| Sun, 2013 [ | China | 85 (43/42) | 73.00 ± 10.56/74.83 ± 8.84 | Estazolam (1 mg, Qd) | Cowherb seed ear beans (Xin, Shenmen, Pizhixia, etc.), 3 min, Tid) | 28 | ①, ② |
| Tang and Zhang, 2015 [ | China | 65 (31/34) | 59.68 ± 8.73/58.25 ± 9.31 | Estazolam (2 mg, Qd) | Acupuncture (Shenting-GV24, Benshen-GB13, Shenmen-HT7, etc.), 30 min, 5 times/week | 28 | ①, ② |
| Wu et al., 2020 [ | China | 76 (38/38) | 59.31 ± 3.51/58.22 ± 3.42 | Estazolam (1 mg, Qd) | Estazolam + acupuncture (Baihui-GV20, Shenting-GV24, Yintan-GV29, Sishencong- EX-HN1, etc.), 30 min, Qd, 6 times/week | 28 | ①, ② |
| Wang et al., 2018 [ | China | 152 (76/76) | 64.00 ± 6.00/64.00 ± 6.00 | Zopiclone (3 mg, Qd) | Zopiclone + acupuncture (Baihui-GV20, Taiyang-EX-HN5 Zusanli-ST36), 20–30 min, Qd | 28 | ①, ② |
| Xie, 2018 [ | China | 83 (40/43) | 58.15 ± 12.20/56.94 ± 9.83 | Estazolam (2 mg, 4–6 times/week) | Acupuncture (Sanyinjiao-SP6, Shenmen-HT7, Sishencong-EX-HN1, Taichong-LR3, Neiguan-PC6, Taixi-KI3, etc), 20–30 min, 6 times/week | 28 | ①, ②, ③ |
| Xu et al., 2012 [ | China | 60 (30/30) | 62.40 ± 4.78/62.48 ± 3.66 | Diazepam (5 mg, Qd) | Acupuncture (Shenting-GV24, Baihui-GV20, Fengfu-GV16, Shendao-GV11, Sishencong-EX-HN1), 30 min, 6 times/week | 28 | ①, ② |
| Yang, 2015 [ | China | 65 (32/33) | 63.20 ± 7.21/65.20 ± 7.64 | Estazolam (2 mg, Qd) | Moxibustion (Dazhui-GV14 to Yaoyangguan-GV3), 45 min, 3 times/week | 90 | ①, ② |
| Ye et al., 2010 [ | China | 60 (30/30) | 62.40 ± 4.88/61.48 ± 3.72 | Diazepam (5.0 mg, Qd) | Acupuncture (Shenting-GV24, Baihui-GV20, Fengfu-GV16, Shendao-GV11, Sishencong-EX-HN1), 30 min, 6 times/week | 28 | ① |
| Zhang, 2012 [ | China | 80 (40/40) | 60.4/58.7 | Diazepam 2.5 mg or estazolam 1 mg, Qd | Acupuncture (Shenmen-HT7, Baihui-GV20, Shenting-GV24, etc.) + auricular acupuncture (Xin, Pi, Shenmen, Jiaogan), 30 min, 6 times/week | 28 | ①, ② |
| Zhang and Zhau, 2016 [ | China | 71 (36/35) | 74.70 ± 13.10/74.40 ± 9.38 | Estazolam | Estazolam + auricular point pressing (Pizhixia, Shenmen, Shenjingshuairuoqu, Zhen, etc.), 3 min, 2 times/week | 40 | ② |
| Zhuang and Jiang, 2014 [ | China | 99 (50/49) | 61.06 ± 8.72/63.88 ± 8.07 | Estazolam (1 mg, Qd) | Acupuncture (Sishencong-EX-HN1, Neiguan-PC6, Shenmen-HT7, Laogong-PC8, etc.), 30 min, Qd | 30 | ② |
Note. “-”: not mentioned; ①: total effective rate; ② Pittsburgh sleep quality index (PSQI); ③ adverse reactions.
Diagnostic criteria of the included literature.
| Study cohort | Country | Stroke | Insomnia |
|---|---|---|---|
| Gao et al., 2009 [ | China | Diagnostic points of various cerebrovascular diseases | Diagnosis and treatment of insomnia |
| Hao et al., 2016 [ | China | Diagnostic criteria of integrated traditional Chinese and western medicine for cerebral infarction and cerebral hemorrhage | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Hou et al., 2018 [ | China | Diagnostic points of various cerebrovascular diseases | Diagnosis and treatment of insomnia |
| Huang et al., 2019 [ | China | Diagnostic points of various cerebrovascular diseases | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Jia et al., 2010 [ | China | Diagnostic criteria of integrated traditional Chinese and western medicine for cerebral infarction and cerebral hemorrhage | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Ji, 2016 [ | China | Chinese guidelines for diagnosis and treatment of acute ischemic stroke | ICD-10 Classification of Mental and Behavioural Disorders |
| Li, 2007 [ | China | Diagnostic points of various cerebrovascular diseases | Diagnosis and treatment of insomnia |
| Li, 2015 [ | China | Diagnostic points of various cerebrovascular diseases | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Liu et al., 2006 [ | China | Diagnostic points of various cerebrovascular diseases | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Liu, 2017 [ | China | Diagnostic points of various cerebrovascular diseases | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Liu and Zhang, 2017 [ | China | Chinese guidelines for diagnosis and treatment of acute ischemic stroke | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Lu et al., 2008 [ | China | Criteria for diagnosis and efficacy assessment of apoplexy | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Ma et al., 2016 [ | China | Diagnostic points of various cerebrovascular diseases | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Mi et al., 2009 [ | China | Diagnostic points of various cerebrovascular diseases | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Qin et al., 2019 [ | China | Guidelines for prevention and treatment of cerebrovascular diseases in China | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Sun, 2013 [ | China | Diagnostic points of various cerebrovascular diseases | Diagnosis and treatment of insomnia |
| Tang and Zhang, 2015 [ | China | Diagnostic points of various cerebrovascular diseases | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Wu et al., 2020 [ | China | Guidelines for prevention and treatment of cerebrovascular diseases in China | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Wang et al., 2018 [ | China | Chinese guidelines for diagnosis and treatment of acute ischemic stroke | ICD-10 Classification of Mental and Behavioural Disorders |
| Xie, 2018 [ | China | Diagnostic points of various cerebrovascular diseases | PSQI > 7 |
| Xu et al., 2012 [ | China | Criteria for diagnosis and efficacy assessment of apoplexy | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Yang, 2015 [ | China | Guidelines for prevention and treatment of cerebrovascular diseases in China | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Ye et al., 2010 [ | China | Diagnostic points of various cerebrovascular diseases | Diagnosis and treatment of insomnia |
| Zhang, 2012 [ | China | Diagnostic points of various cerebrovascular diseases | Diagnosis and treatment of insomnia |
| Zhang and Zhou, 2016 [ | China | Guidelines for prevention and treatment of cerebrovascular diseases in China | The Chinese Classification of Mental Disorders (CCMD-3), 3rd ed. |
| Zhuang and Jiang, 2014 [ | China | Diagnostic points of various cerebrovascular diseases | PSQI > 7 |
Figure 2Risk-of-bias assessment results of the included studies.
Figure 3Forest plot of the clinical effective rate between the two groups.
Figure 4Forest plot of the subgroup analysis in the clinical effective rate between the two groups.
Figure 5Forest plot of PSQI between the two groups.
Figure 6Forest plot of the subgroup analysis in PSQI between the two groups.
Figure 7Forest plot of adverse reactions between the two groups.
Figure 8Sensitivity analysis of the total effective rate.
Figure 9Sensitivity analysis of PSQI.
Figure 10Sensitivity analysis of adverse reactions.
Figure 11The funnel plot of the effective rate.
GRADE summary table of the outcome indicators evidence quality.
| Acupuncture compared to drug for poststroke insomnia | |||||
|---|---|---|---|---|---|
| Patient or population: patients with poststroke insomnia | |||||
| Intervention: acupuncture | |||||
| Comparison: drug | |||||
| Outcomes | Illustrative comparative risks | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) | |
| Assumed risk | Corresponding risk | ||||
| Drug | Acupuncture | ||||
| Clinical effective rate | Study population | RR 1.23 (1.18 to 1.29) | 1686 (24 studies) | ⊕⊕⊝⊝low1,2 | |
| 749 per 1000 | 921 per 1000 (884 to 966) | ||||
| Medium risk population | |||||
| 767 per 1000 | 943 per 1000 (905 to 989) | ||||
| PQSI score | The mean PQSI score in the intervention groups was 3.41 higher (2.4 to 4.41 higher) | 1606 (22 studies) | ⊕⊕⊝⊝low1,2 | ||
| Adverse reactions | Study population | RR 0.17 (0.09 to 0.32) | 353 (5 studies) | ⊕⊝⊝⊝very low1,2,3 | |
| 309 per 1000 | 53 per 1000 (28 to 99) | ||||
| Medium risk population | |||||
| 200 per 1000 | 34 per 1000 (18 to 64) | ||||
The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio; GRADE: working group grades of evidence. High quality: further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: we are very uncertain about the estimate. 1Some of the studies did not describe randomization, and none of the studies described blinding of participants and personnel, as well as blinding of outcome assessment. 2Funnel plot test showed publication bias in the results. 3Downgrading a notch was conducted because the number of included studies is small, and the confidence interval is wide.